Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

Blood

Volumn 96, Issue 12, 2000, Pages 3948-3952

  Venditti, Adriano ^a   Buccisano, Francesco ^a   Del Poeta, Giovanni ^a   Maurillo, Luca ^a   Tamburini, Anna ^a   Cox, Christina ^a   Battaglia, Alessandra ^a   Catalano, Gianfranco ^a   Del Moro, Beatrice ^a   Cudillo, Laura ^a   Postorino, Massimiliano ^a   Masi, Mario ^a   Amadori, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL PROTOCOL; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; TREATMENT OUTCOME;

EID: 0034554848     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3948     Document Type: Article

References (27)

1. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC 10 trial
2. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia
3. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia
4. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
5. Intensive postremission chemotherapy in adults with acute myeloid leukemia
6. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
7. Genetic diagnosis and molecular monitoring in the management of promyelocytic leukemia
8. Therapy of molecular relapse in acute promyelocytic leukemia
9. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse
10. Detection of minimal residual disease in acute leukemia: Methodological advances and clinical significance
11. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients
12. Myeloid cell differentiation in normal bone marrow and acute myeloid leukemia assessed by multi-dimensional flow cytometry
13. Flow cytometry characterization of acute myeloid leukemias. II. Phenotypic heterogeneity at diagnosis
14. The amount of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
15. Comparison of three intercalating agents in induction and consolidation in acute myelogenous leukemia (AML) followed by autologous or allogeneic transplantation: Preliminary results of the EORTC-GIMEMA AML-10 randomized trial
16. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia
17. + hematopoietic progenitor cells for clinical transplantation: Comparison of three different methods
18. Triple immunofluorescence evaluation of CD15, CD34 and class II expression by flow cytometry in normal and leukemic bone marrows
19. Increased light scattering resolution facilitates multidimensional flow cytometric analysis
20. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia
21. Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia
22. Nonparametric estimations from incomplete observations
23. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
24. Minimal residual disease by flow cytometry immediately before autologous stem cell transplantation in acute myeloid leukemia: A critical factor in outcome?
25. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
26. Mobilization of high numbers of autologous blood stem cells for patients with AML is associated with poor outcome: Results of the EORTC-GIMEMAAML-10 amended trial